Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis,Journal of Hepato-Biliary-Pancreatic Sciences

当前位置： X-MOL 学术 › J. Hepato Biliary Pancreat. Sci. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis
Journal of Hepato-Biliary-Pancreatic Sciences ( IF 3.2 ) Pub Date : 2021-06-04 , DOI: 10.1002/jhbp.1005
Daigoro Takahashi ₁ , Takashi Mizuno ₁ , Yukihiro Yokoyama ₁ , Tsuyoshi Igami ₁ , Junpei Yamaguchi ₁ , Shunsuke Onoe ₁ , Nobuyuki Watanabe ₁ , Osamu Maeda ₂ , Masahiko Ando ₃ , Tomoki Ebata ₁

Affiliation

The efficacy of adjuvant chemotherapy for biliary cancers remains controversial because of conflicting results from previous phase 3 studies that used different key drugs and enrolled patients with heterogeneous tumor sites and disease stages. Fluoropyrimidine seems more beneficial than gemcitabine (GEM) combination regimens in the adjuvant setting; however, data comparing the survival benefit between GEM- and fluoropyrimidine-based regimens are lacking.

中文翻译：

辅助 S-1 与吉西他滨治疗淋巴结阳性肺门周围胆管癌：倾向评分调整分析

辅助化疗对胆道癌的疗效仍然存在争议，因为之前的 3 期研究结果相互矛盾，这些研究使用了不同的关键药物并招募了具有异质肿瘤部位和疾病阶段的患者。在辅助治疗中，氟嘧啶似乎比吉西他滨 (GEM) 联合方案更有益；然而，缺乏比较基于 GEM 和基于氟嘧啶的方案的生存获益的数据。

更新日期：2021-06-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11